scPharmaceuticals Inc. announced the appointment of two directors to its board of directors. Minnie Baylor-Henry, formerly with Johnson & Johnson, and Mason Freeman, M.D., a venture partner at 5AM ventures, have joined the scPharmaceuticals board. Simultaneously with Dr. Freeman’s appointment to the Company’s Board of Directors, Kush Parmar M.D., Ph.D. also of 5AM Ventures, stepped down from the Board after serving since the formation of the Company. Ms. Baylor-Henry has over 20 years regulatory affairs experience and is a recognized leader in strategically handling complex regulatory and policy affairs for companies in the life sciences industry. Currently, Minnie is the President of B-Henry & Associates. Prior to her work at B-Henry, Ms. Baylor-Henry held multiple positions at Johnson & Johnson, including as the Worldwide Vice President, Regulatory Affairs-Medical Devices and as Vice President, Medical & Regulatory Affairs of the Specialty Pharmaceuticals and Over-the-Counter Products (McNeil Consumer Health Care Division). Dr. Freeman is a venture partner at 5AM Ventures, which he joined initially as scientific advisor in 2007. In addition to his work at 5AM Ventures, Dr. Freeman serves as Chief of the Lipid Metabolism Unit and director of translational medicine at Massachusetts General Hospital and is a professor at Harvard Medical School. Dr. Freeman currently serves on the Board of Directors of Crinetics Pharmaceuticals, is on the Scientific Advisory Board of Homology Medicines Inc., and Mitobridge Inc.